Skip to main content
≥99.0% HPLC Verified • SEPA Bank & Crypto • Min. Order €220
Metabolic Research 4 min read

Retatrutide (LY3437943): Molecular Structure, GIP/GLP-1/Glucagon Triple Receptor Agonism, and Metabolic Bioassays

Compiled & reviewed by SwissLab Bioenergetics & Compliance Desk — Cellular Bioenergetics, Neuropeptides & RUO Governance Desk
Editorial Standards
Analytical Summary

A technical dissection of the novel unimolecular peptide tri-agonist Retatrutide (LY3437943). Binding kinetics across GIPR, GLP-1R, and GCGR, C20 fatty diacid conjugation, and energy expenditure assays. Retatrutide is a single 39-amino-acid peptide backbone engineered with balanced tri-agonism against GIP, GLP-1, and Glucagon receptors.

Key Research Takeaways
  • Retatrutide is a single 39-amino-acid peptide backbone engineered with balanced tri-agonism against GIP, GLP-1, and Glucagon receptors.
  • Features an alpha-methyl-L-tyrosine at position 1 and a C20 diacid fatty acyl chain conjugated at position 17 for extended albumin half-life (~6 days).
  • Glucagon receptor activation directly stimulates hepatic lipolysis, fat oxidation, and thermogenesis beyond dual GIP/GLP-1 agonists.
  • Synthesized via microwave-assisted solid-phase peptide synthesis (SPPS) and validated by RP-HPLC at ≥99% analytical purity.
Analytical & Handling Reference Matrix
CAS Registry Number 2381089-83-2
Molecular Formula C221H342N46O68
Molecular Mass 4731.33 g/mol
Primary Biological Target GIPR (EC50 0.077 nM), GLP-1R (EC50 0.77 nM), GCGR (EC50 0.57 nM)
Analytical Purity Standard ≥99.0% (RP-HPLC, C18, 214/220 nm)
Identity Verification ESI-MS (±0.1 Da) + Karl Fischer Moisture (<3.0%)
Lyophilized Storage -20°C desiccated, protected from UV light (24–36 months)
Reconstituted Storage 2°C–8°C refrigerated (up to 28 days in 0.9% BA BAC water)

1. Molecular Structure and Rational Sequence Engineering

Retatrutide (LY3437943) represents the third generation of incretin-based metabolic peptides. Its primary sequence is derived from the GIP peptide backbone, containing deliberate non-coded amino acid substitutions to achieve dual-incretin plus glucagon receptor engagement. The N-terminus begins with alpha-methyl-L-tyrosine (alpha-Me-Tyr) at position 1, providing enzymatic resistance against dipeptidyl peptidase-4 (DPP-4) cleavage. At position 17, a modified lysine residue is covalently linked via a [2-(2-aminoethoxy)ethoxy]acetyl linker to a C20 diacid fatty acyl moiety (icosanedioic acid). This fatty acid chain non-covalently binds endogenous serum albumin, retarding renal filtration and enabling a biological half-life of approximately 144 hours.

2. Receptor Affinity and In-Vitro Potency Profile

Quantitative cyclic AMP (cAMP) accumulation assays demonstrate that Retatrutide acts as a potent full agonist across all three human target receptors: human GIP receptor (EC50 = 0.077 nM), human GLP-1 receptor (EC50 = 0.77 nM), and human Glucagon receptor (EC50 = 0.57 nM). Compared to Tirzepatide (which lacks GCGR activity), Retatrutide exhibits approximately 3-fold higher potency at GIPR and balanced nanomolar engagement at GLP-1R and GCGR. This tri-modal signaling cascade simultaneously promotes insulin secretagogue action (GIP/GLP-1), central satiety signaling in the arcuate nucleus, and glucagon-driven lipid mobilization.

3. Hepatic and Adipocyte Metabolic Pathways

The defining pharmacological characteristic of Retatrutide is its recruitment of glucagon receptor signaling in hepatocytes. In rodent and primary human hepatocyte cultures, GCGR activation stimulates cyclic AMP/protein kinase A (cAMP/PKA) phosphorylation of hormone-sensitive lipase (HSL) and increases carnitine palmitoyltransferase 1 (CPT-1) expression, driving hepatic beta-oxidation of fatty acids and decreasing de-novo lipogenesis. Concurrently, GIP and GLP-1 agonism buffer against glucagon-mediated hepatic glucose output by enhancing glucose-dependent insulin release.

4. Laboratory Reconstitution and Handling Parameters

Retatrutide is supplied as a sterile lyophilized white powder in neutral glass vials. Due to its hydrophobic C20 fatty diacid chain, reconstitution requires gentle addition of sterile Bacteriostatic Water USP (0.9% benzyl alcohol) at room temperature. The solution reaches clarity within 60 to 90 seconds without vigorous agitation. Reconstituted stock solutions should be maintained at 2°C to 8°C and protected from light, maintaining chromatographic purity for 28 days.

5. Bench Preparation & Assay Reproducibility for Retatrutide (LY3437943)

When designing in-vitro experiments targeting GIPR (EC50 0.077 nM), GLP-1R (EC50 0.77 nM), GCGR (EC50 0.57 nM), normalize dosing across replicates by molar concentration (µM or nM) using the published molecular weight (4731.33 g/mol) and batch counterion composition rather than gross powder weight alone. Log lot numbers, diluent pH, and aliquot dates to ensure batch-to-batch reproducibility across longitudinal experiments.

Peer-Reviewed References & Analytical Standards

  1. Coskun T. et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metabolism, 34(9), 1234–1247. [PMID: 35985340 ↗]
  2. Jastreboff A.M. et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. New England Journal of Medicine, 389(6), 514–526. [PMID: 37366315 ↗]

Referenced Laboratory Research Reagents

Batch-verified SwissLab catalog entries cited in this monograph

All 66 Compounds →
Laboratory Compliance & Handling Protocol

All analytical monographs and chemical data are published strictly for in-vitro laboratory research and scientific reference. Reagents must be handled by qualified personnel wearing appropriate PPE. Not for human or veterinary use.

Related Research Monographs

All monographs (44)

Your Research Cart

0 items selected • Min. order €220

SEPA Bank Transfer & Crypto (BTC, ETH, USDT, USDC, SOL, XMR)
Min €220

Your cart is empty

Browse our catalog of research peptides and reagents (minimum order €220).

Browse Catalog